Alnylam Pharmaceuticals Inc (ALNY)
131.03
-2.09 -1.57%
NASDAQ
Feb 21, 20:00
Delayed 2m
USD
View All Key Stats
Key Stats
| Income Statement | |
| Revenue (TTM) | 219.75M |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (TTM) | -8.14 |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Net Income (TTM) | -886.12M |
| Profitability | |
| Gross Profit Margin (Quarterly) | 83.01% |
| Profit Margin (Quarterly) | -385.3% |
| Dividend | |
| Dividend Yield (Forward) | Upgrade |
| Dividend Yield | 0.00% |
| Price and Valuation | |
| Market Cap | 14.75B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| PS Ratio | 64.76 |
| PE Ratio | -- |
| Price to Book Value | 10.25 |
| Other | |
| Beta (5Y) | Upgrade |
| Debt to Equity Ratio | 0.00 |
| Free Cash Flow (Quarterly) | -234.78M |
| Return on Equity | Upgrade |
View All ALNY News
News
-
WireHeadlineTime (ET)
-
Business Wire02/20 08:00
-
SA Breaking News02/18 10:04
-
MT Newswires02/18 09:48
-
Yahoo02/18 08:00
-
Business Wire02/18 07:00
-
Yahoo02/11 17:54
-
MT Newswires02/11 10:55
-
PR Newswire02/11 09:31
-
Yahoo02/10 20:44
-
SA Breaking News02/07 15:52
View All Events
Events
| Date | Type | Description |
|---|---|---|
| 05/01/2020 20:30 EDT | Misc | Alnylam Pharmaceuticals Inc First Quarter Earnings Conference Call in 2020 |
| 05/01/2020 | Earnings | Alnylam Pharmaceuticals Inc First Quarter Earnings in 2020 Release |
| 02/06/2020 08:30 EST | Misc | Alnylam Pharmaceuticals Inc Fourth Quarter Earnings Conference Call for 2019 |
| 02/06/2020 | Earnings | Alnylam Pharmaceuticals Inc Fourth Quarter Earnings in 2019 Release |
| 10/31/2019 08:30 EDT | Misc | Alnylam Pharmaceuticals Inc Third Quarter Earnings Conference Call for 2019 |
| 10/31/2019 | Earnings | Alnylam Pharmaceuticals Inc Third Quarter Earnings in 2019 Release |
| 08/06/2019 08:00 EDT | Misc | Alnylam Pharmaceuticals Inc Second Quarter Earnings Conference Call in 2019 |
| 08/06/2019 | Earnings | Alnylam Pharmaceuticals Inc Second Quarter Earnings in 2019 Release |
| 05/01/2019 20:30 EDT | Misc | Alnylam Pharmaceuticals Inc First Quarter Earnings Conference Call in 2019 |
| 05/01/2019 | Earnings | Alnylam Pharmaceuticals Inc First Quarter Earnings in 2019 Release |
Fundamentals
Income Statement View Statement
Ratings & Reports
- Y-Rating Upgrade
- Value Score Upgrade
- Fundamental Score Upgrade
- Valuation (Hist. Mult.) Upgrade
- Y-Rating Report Download
- One Page Report Download
Advertisement
Edit
Profile
- URL: https://www.alnylam.com
- Investor Relations URL: http://investors.alnylam.com/index.cfm
- HQ State/Province: Massachusetts
- Sector: Healthcare
- Industry: Biotechnology
- Equity Style: Mid Cap/Growth
- Next Earnings Release: May. 01, 2020
- Last Earnings Release: Feb. 06, 2020
- Next Ex-Dividend Date: N/A
- Last Ex-Dividend Date: N/A
- Description: Alnylam Pharmaceuticals is a leader in the study of RNA interference and is attempting to harness this mechanism to create a new class of drugs. In addition to FDA-approved patisiran (Onpattro) for amyloidosis and givosiran (Givlaari) for acute hepatic porphyria (AHP), Alnylam has several partnered several pipeline candidates in rare genetic diseases, liver diseases, and other indications as well. Up-front fees from research partnerships with firms such as Regeneron, Sanofi, and The Medicines Company have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
Analyst Coverage
| Consensus Recommendations | |
| Buy Recommendations | Upgrade |
| Outperform Recommendations | Upgrade |
| Hold Recommendations | Upgrade |
| Underperform Recommendations | Upgrade |
| Sell Recommendations | Upgrade |
| Consensus Recommendation | Upgrade |
| Consensus Rating | Upgrade |
| Target Price | |
| Price | 131.03 |
| Price Target | Upgrade |
| Price Target Upside (Daily) | Upgrade |
Top Fund Holders
| Symbol | Name | Weighting |
|---|---|---|
| BBH | VanEck Vectors Biotech ETF | 4.02% |
| FBT | First Trust NYSE Arca Biotech ETF | 3.59% |
| FXH | First Trust Health Care AlphaDEX® ETF | 2.42% |
| VGHCX | Vanguard Health Care Inv | 2.22% |
| FBIOX | Fidelity® Select Biotechnology | 2.03% |
| KLCKX | Federated Kaufmann Large Cap R | 1.97% |
| XBI | SPDR® S&P Biotech ETF | 1.89% |
| IBB | iShares Nasdaq Biotechnology ETF | 1.77% |
| FCGSX | Fidelity® Series Growth Company | 1.37% |
| HFMRX | Hartford MidCap R3 | 1.36% |
| FGCKX | Fidelity® Growth Company K | 1.36% |
| SCHM | Schwab US Mid-Cap ETF™ | 0.43% |
Other Resources
- 13F Filings Whale Wisdom
- Call Transcripts Seeking Alpha
- Insider Trading Morningstar
- Institutional Ownership Nasdaq
- SEC Filings SEC
- ALNY Tweets Stocktwits
Advertisement
